Výsledky vyhledávání - "Pyrimidines / therapeutic use"

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

Autor: Kim Papp, Joseph Wu, Peter Nash, Wolf-Henning Boehncke, Joseph F. Merola, M-A Hsu, Jordi Gratacós, Daniela Graham, Cunshan Wang, P. Young, Diamant Thaçi

Publikováno v: Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820

Background Psoriatic arthritis (PsA) is a chronic, systemic immune‐mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaa37b863c214fdc12f3c4ac179bfca8
http://europepmc.org/articles/PMC7818414

Zobrazit plný text záznamu

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis

Autor: Barbara Tomic, Tomislav Smoljo, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Drago Batinic, Antonio Bedalov, Dora Visnjic

Acute myeloid leukemia (AML) is characterized by arrested differentiation making differentiation therapy a promising treatment strategy. Recent success of inhibitors of mutated isocitrate dehydrogenase (IDH) invigorated interest in differentiation th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d328b03c9280a3fbd95f7362c438e671
https://www.bib.irb.hr/1211738

Zobrazit plný text záznamu

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Autor: Antoinette R. Tan, Gail S. Wright, Anu R. Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richards, Sharon T. Wilks, Dušan Milenković, Jie Xiao, Jessica Sorrentino, Janet Horton, Joyce O'Shaughnessy

Purpose: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8917e851089d75b5c0c66a5c1255f89b
https://www.bib.irb.hr/1193911

Zobrazit plný text záznamu

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia:5-year update of the ENESTfreedom trial

Autor: Jerald P. Radich, David M. Ross, Bruno Martino, Susanne Saussele, María Teresa Gómez Casares, Andreas Hochhaus, Eibhlin Conneally, Giuseppe Saglio, Philipp le Coutre, Norbert Gattermann, Tamás Masszi, Sai Li, Francis J. Giles, Jesper Stentoft, Andrzej Hellmann, Paola Aimone, Ksenia Titorenko, J. Valentín García-Gutiérrez

Publikováno v: Radich, J P, Hochhaus, A, Masszi, T, Hellmann, A, Stentoft, J, Casares, M T G, García-Gutiérrez, J V, Conneally, E, le Coutre, P D, Gattermann, N, Martino, B, Saussele, S, Giles, F J, Ross, D M, Aimone, P, Li, S, Titorenko, K & Saglio, G 2021, ' Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia : 5-year update of the ENESTfreedom trial ', Leukemia, vol. 35, no. 5, pp. 1344-1355 . https://doi.org/10.1038/s41375-021-01205-5
Leukemia

The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b2998b5b263037b3d3f86c7e5684fc
https://pure.au.dk/portal/da/publications/treatmentfree-remission-following-frontline-nilotinib-in-patients-with-chronic-phase-chronic-myeloid-leukemia(8a362493-6e7f-4345-a1da-c05d5478eeb8).html

Zobrazit plný text záznamu

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Publikováno v: Annals of the Rheumatic Diseases, Vol. 80, No 1 (2021) pp. 71-87

Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1400::1182f33d31346539fe8ba8ba42fbc434
https://archive-ouverte.unige.ch/unige:154811

Zobrazit plný text záznamu

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Autor: Finckh, Axel, Tellenbach, C, Herzog, L, Scherer, A, Moeller, B, Ciurea, A, von Muehlenen, I, Gabay, Cem, Kyburz, D, Brulhart, Laure Sophie, Müller, R, Hasler, P, Zufferey, P, physicians and patients of the SCQM (Swiss Clinical Quality Management in Rheumatic Diseases)

Publikováno v: RMD Open, Vol. 6, No 1 (2020) P. e001174
RMD Open
RMD Open, Vol 6, Iss 1 (2020)

BackgroundMultiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c113cafe8cadf519c45d41d35142d2cd
https://hdl.handle.net/11475/25911

Zobrazit plný text záznamu

Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial

Autor: Burkert, Pieske, Mahesh J, Patel, Cynthia M, Westerhout, Kevin J, Anstrom, Javed, Butler, Justin, Ezekowitz, Adrian F, Hernandez, Joerg, Koglin, Carolyn S P, Lam, Piotr, Ponikowski, Lothar, Roessig, Adriaan A, Voors, Christopher M, O'Connor, Paul W, Armstrong, Jian, Zhang

Publikováno v: Pieske, B, Patel, M J, Westerhout, C M, Anstrom, K J, Butler, J, Ezekowitz, J, Hernandez, A F, Koglin, J, Lam, C S P, Ponikowski, P, Roessig, L, Voors, A A, O'Connor, C M, Armstrong, P W & VICTORIA Study Group 2019, ' Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial ', European Journal of Heart Failure, vol. 21, no. 12, pp. 1596-1604 . https://doi.org/10.1002/ejhf.1664
European Journal of Heart Failure
European Journal of Heart Failure, 2019, 21 (12), pp.1596-1604. ⟨10.1002/ejhf.1664⟩
European Journal of Heart Failure, 21(12), 1596-1604. Wiley

International audience; Aim: Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c0559faf46b4ff186b6cd3dfba3f3e
https://pure.au.dk/portal/da/publications/baseline-features-of-the-victoria-vericiguat-global-study-in-subjects-with-heart-failure-with-reduced-ejection-fraction-trial(abef0460-5e68-4f8f-9aab-7efe513d1837).html

Zobrazit plný text záznamu

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Autor: Carolyn S P, Lam, Anna, Giczewska, Karen, Sliwa, Frank, Edelmann, Jens, Refsgaard, Edimar, Bocchi, Justin A, Ezekowitz, Adrian F, Hernandez, Christopher M, O'Connor, Lothar, Roessig, Mahesh J, Patel, Burkert, Pieske, Kevin J, Anstrom, Paul W, Armstrong, Shari, Cook

Publikováno v: Lam, C S P, Giczewska, A, Sliwa, K, Edelmann, F, Refsgaard, J, Bocchi, E, Ezekowitz, J A, Hernandez, A F, O'Connor, C M, Roessig, L, Patel, M J, Pieske, B, Anstrom, K J, Armstrong, P W & VICTORIA Study Group 2021, ' Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event : Insights From the VICTORIA Trial ', JAMA cardiology, vol. 6, no. 6, pp. 706-712 . https://doi.org/10.1001/jamacardio.2020.6455
JAMA Cardiol

Importance: The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH.Objective: To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4273aa570e29339fc6fe0ead57ebeb37
https://doi.org/10.1001/jamacardio.2020.6455

Zobrazit plný text záznamu

Evaluation of Macitentan in Patients With Eisenmenger Syndrome

Autor: Gatzoulis, M.A., Landzberg, M., Beghetti, M., Berger, R.M., Efficace, M., Gesang, S., He, J., Papadakis, K., Pulido, T., Galiè, N.

Publikováno v: Circulation, vol. 139, no. 1, pp. 51-63

Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::bfe35a2b36e413c7337ccb8cf1df5ac1
https://serval.unil.ch/notice/serval:BIB_2B3253EE0026

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání